Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$25,000.00

Bioprinting novel 3D tissues with human ES-derived pancreatic beta cells to regulate blood glucose via the appropriate release of insulin

EF 2017-18

Résumé
The goal of this project is to develop an implantable bioprinted 3D tissue containing stem cell-derived betacells within a network of tubes, that demonstrates high cell viability and appropriate insulin-releasingcapability. The project represents a new collaboration between two leading Canadian technology developers:Aspect, a Vancouver-based company focused on the development and commercialization of 3D bioprintingtechnology, and the University of BC laboratory of Dr. Timothy Kieffer, where protocols have been developedfor the production of insulin producing cells from human embryonic stem (ES) cells. The Kieffer lab willprovide Aspect with human ES cells that have been differentiated into pancreatic progenitor cells or beyond(towards mature beta cells) where they will be bioprinted by Aspect into living biocompatible 3D structuresusing Aspect's unique alginate/collagen bioink. The bioprinted tissues will then be rigorously characterized forcell viability, maturation, and insulin production in response to nutrients, both in vitro and following implantinto mice. Subsequent studies will explore strategies to improve graft vascularization while also assessing theimmunoprotective aspects of the bioprinted tissue. The project will provide an excellent training opportunityfor students in cutting edge biomedical engineering at the interface of academia and industry, and could lead tosubstantial investments in follow-up research and development.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
520826-2017
Name nom
Kieffer, Timothy
Department département
Cellular and Physiological Sciences
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
1
Nb partie
1
Application title
Bioprinting novel 3D tissues with human ES-derived pancreatic beta cells to regulate blood glucose via the appropriate release of insulin
Keyword
NSERC
Application summary
The goal of this project is to develop an implantable bioprinted 3D tissue containing stem cell-derived betacells within a network of tubes, that demonstrates high cell viability and appropriate insulin-releasingcapability. The project represents a new collaboration between two leading Canadian technology developers:Aspect, a Vancouver-based company focused on the development and commercialization of 3D bioprintingtechnology, and the University of BC laboratory of Dr. Timothy Kieffer, where protocols have been developedfor the production of insulin producing cells from human embryonic stem (ES) cells. The Kieffer lab willprovide Aspect with human ES cells that have been differentiated into pancreatic progenitor cells or beyond(towards mature beta cells) where they will be bioprinted by Aspect into living biocompatible 3D structuresusing Aspect's unique alginate/collagen bioink. The bioprinted tissues will then be rigorously characterized forcell viability, maturation, and insulin production in response to nutrients, both in vitro and following implantinto mice. Subsequent studies will explore strategies to improve graft vascularization while also assessing theimmunoprotective aspects of the bioprinted tissue. The project will provide an excellent training opportunityfor students in cutting edge biomedical engineering at the interface of academia and industry, and could lead tosubstantial investments in follow-up research and development.